Truist analyst Srikripa Devarakonda raised the firm’s price target on Septerna (SEPN) to $35 from $34 and keeps a Buy rating on the shares. The firm is incrementally positive on the company after its Q4 update, where clinical trial timelines remain on track, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEPN:
- Septerna files automatic mixed securities shelf
- Septerna: Novo-Backed GPCR Platform and Best-in-Class Potential for Oral MRGPRX2 Inhibitor SEP-631 Support Buy Rating
- Septerna reports Q4 EPS (24c), consensus (22c)
- Septerna (SEPN): Early Proof-of-Concept for SEP-631 in Mast Cell–Driven Disease Supports Long-Term Growth Potential
- Septerna price target raised to $40 from $35 at H.C. Wainwright